



165 – 10551 Shellbridge Way  
Richmond, BC, V6X 2W8

## **BioMark Diagnostics Engages LHA for Investors Relations**

**VANCOUVER, British Columbia – (June 29, 2015)** – BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCQB: BMKDF) announces that it has engaged LHA to support its investor relations program in the U.S. market.

“We recognize the importance of expanding our investor relations outreach,” said BioMark President and CEO Rashid Ahmed. “In recent years, the U.S. investment community has shown significant interest in the biotechnology sector and we are excited to introduce BioMark and our novel, disruptive technology to this receptive market. Given their understanding of the opportunity, and proven track record for establishing messaging that resonates with investors and increasing Street awareness for companies like BioMark, we view LHA as an ideal choice. LHA is the right partner for BioMark at the right time.”

### About LHA

Founded in 1984, LHA (formerly Lippert Heilshorn & Associates) is a leading provider of investor relations services. Staffed by a team of professionals with deep experience across multiple industry sectors, LHA partners with public and private companies to define objectives, set strategy and implement custom-designed programming utilizing industry best practices. By creating client identity and communicating strategic vision, LHA builds awareness, enthusiasm and sponsorship among target audiences to maximize shareholder value.

### About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions that can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. For more information, please visit [www.biomarkdiagnostics.com](http://www.biomarkdiagnostics.com).

Further information about BioMark is available under its profile on the SEDAR website [www.sedar.com](http://www.sedar.com) and on the CSE website [www.thecse.ca](http://www.thecse.ca).

### **Company Contact**

Rashid Ahmed Bux  
President & CEO

BioMark Diagnostics Inc.  
604-282-6567

[info@biomarkdiagnostics.com](mailto:info@biomarkdiagnostics.com)

**Investor Contact**

LHA

Jody Cain

310-691-7100

[jcain@lhai.com](mailto:jcain@lhai.com)**Forward-Looking Information:**

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

**The CSE has not reviewed, approved or disapproved the content of this press release.**